Literature DB >> 6866051

Steroid-induced fractures and bone loss in patients with asthma.

A D Adinoff, J R Hollister.   

Abstract

To study the association between bone disease and long-term steroid administration in asthmatics, we reviewed the hospital records of 128 patients over 40 years of age who had taken daily or alternate-day adrenal corticosteroids for at least a year and compared them with the records of 54 other asthmatics of similar age who had not required long-term administration of steroids. We found evidence in the records of a total of 58 fractures of the ribs or vertebrae in 14 of the patients who had received long-term steroid treatment (11 per cent) and no evidence of fractures in the patients who had not received long-term treatment. We also prospectively studied 30 hospitalized asthmatic patients between 20 and 70 years of age who had been screened for medications (other than steroids) or complicating diseases known to affect bone mineralization. Eight of 19 asthmatic patients receiving long-term steroid therapy had rib or vertebral fractures, whereas none of 11 matched patients not receiving such therapy had fractures. Furthermore, bone-density measurements of the distal and proximal radius by photon absorptiometry revealed that the trabecular, but not the cortical, bone mass was below normal in the former group of patients but not in the latter. Within the long-term steroid group, there was no significant correlation between bone density and dose or duration of steroid treatment. We conclude that long-term steroid therapy in asthmatic patients is associated with decreased trabecular bone density and an increased prevalence of rib and vertebral fractures.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6866051     DOI: 10.1056/NEJM198308043090502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  117 in total

Review 1.  Glucocorticoid-induced osteoporosis.

Authors:  P Boulos; G Ioannidis; J D Adachi
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 2.  Bone loss and glucocorticoid therapy in patients with respiratory disease.

Authors:  A Fairney
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

3.  Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid induced osteoporosis?

Authors:  W F Lems; J W Jacobs; J W Bijlsma; G J van Veen; H H Houben; H C Haanen; M I Gerrits; H J van Rijn
Journal:  Ann Rheum Dis       Date:  1997-06       Impact factor: 19.103

4.  Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease.

Authors:  J Takahashi; K Kawakatsu; T Wakayama; H Sawaoka
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients.

Authors:  I R Reid; M C Evans; D J Wattie; R Ames; T F Cundy
Journal:  Osteoporos Int       Date:  1992-03       Impact factor: 4.507

6.  Steroid induced osteoporosis.

Authors:  W F Lems; J W Bijlsma
Journal:  BMJ       Date:  1992-11-28

7.  The role of glucocorticoids and prostaglandin E2 in the recruitment of bone marrow mesenchymal cells to the osteoblastic lineage: positive and negative effects.

Authors:  A Scutt; P Bertram; M Bräutigam
Journal:  Calcif Tissue Int       Date:  1996-09       Impact factor: 4.333

Review 8.  Endogenous Glucocorticoids and Bone.

Authors:  Hong Zhou; Mark S Cooper; Markus J Seibel
Journal:  Bone Res       Date:  2013-06-28       Impact factor: 13.567

9.  Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.

Authors:  L Dalle Carbonare; F Bertoldo; M T Valenti; S Zordan; S Sella; A Fassina; G Turco; G Realdi; V Lo Cascio; S Giannini
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

Review 10.  Risk factors for osteoporosis and associated fractures.

Authors:  J L Kelsey
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.